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Background: Alzheimer’s disease (AD) as neurodegenerative disorder, is the most common form of dementia
accounting for about 50-60% of the overall cases of dementia among persons over 65 years of age. Low
acetylcholine (ACh) concentration in hippocampus and cortex areas of the brain is one of the main reasons for this
disease. In recent years, acetylcholinesterase (AChE) inhibitors like donepezil with prevention of acetylcholine
hydrolysis can enhance the duration of action of acetylcholine in synaptic cleft and improve the dementia
associated with Alzheimer’s disease.
Results: Design, synthesis and assessment of anticholinesterase activity of 2-(2-(4-Benzylpiperazin-1-yl)ethyl)
isoindoline-1,3-dione derivatives showed prepared compounds can function as potential acetylcholinesterase
inhibitor. Among 12 synthesized derivatives, compound 4a with ortho chlorine moiety as electron withdrawing
group exhibited the highest potency in these series (IC50 = 0.91 ± 0.045 μM) compared to donepezil (IC50 = 0.14 ±
0.03 μM). The results of the enzyme inhibition test (Ellman test) showed that electron withdrawing groups like Cl, F
and NO2 can render the best effect at position ortho and para of the phenyl ring. But compound 4g with methoxy
group at position 3(meta) afforded a favorable potency (IC50 = 5.5 ± 0.7 μM). Furthermore, docking study confirmed
a same binding mode like donepezil for compound 4a.
Conclusions: Synthesized compounds 4a-4l could be proposed as potential anticholinesterase agents.
Keywords: Synthesis, Phthalimide, Acetylcholinesterase (AChE), Anti-Alzheimer, Ellman test, DockingBackground
Alzheimer’s disease (AD), is described by Dr. Alois
Alzheimer in 1907 as a neurodegenerative disorder. AD as
a disease of the central nervous system (CNS) character-
ized especially by premature senile mental deterioration.
AD patients exhibit a significant decrease in cognitive abil-
ity and severe behavioral and psychological abnormalities
such as irritability, anxiety and depression [1]. AD, one of
the most diffuse neurodegenerative pathology among the
elderly, causes a progressive impairment in functional per-
formances and continuous reduction in cognitive activities* Correspondence: aliabadi.alireza@gmail.com
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distribution, and reproduction in any mediumand memory [2-7]. AD is the most common form of
dementia accounting for about 50-60% of the overall cases
of dementia among persons over 65 years of age, is a neu-
rodegenerative alteration characterized by a low acetylcho-
line (ACh) in hippocampus and cortex [8]. AD is said
to be the leading cause of dementia in elderly patients.
Nowadays, with increase of the elderly population, the
prevalence of AD is likely to increase. AD persons exert
a decrease in mental functions and performances and con-
sequently rendering them incapacitated and unable to per-
form normal daily activities. Elderly persons are the most
common individuals afflicted with this disease. Unfortu-
nately, the true nature or cause of the disease is still
unknown and therefore, the development of effective anti-Med Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cinal chemistry researches [1].
Over two decades ago, several autopsy studies inside
hippocampus revealed that the levels of the neurotrans-
mitter acetylcholine in patients with Alzheimer’s disease
are importantly decreased [9]. Currently, the loss of cho-
linergic function is the only evidentiary finding responsible
for cognitive decline. Hence, therapeutical development
has focused on this theory. The loss of the basal forebrain
cholinergic system is one of the most significant aspects of
neurodegeneration in the brains of AD patients, and it is
thought to play a central role in producing cognitive
impairments [1,2,10,11]. Alzheimer’s disease leads to a
progressive decline of the cognitive function, executive
function losses, memory deficits, and eventually to incap-
acitating dementia before death. In order to improve
cholinergic neurotransmission, different strategies have
been investigated including the increase of synthesis or
pre-synaptic release of ACh, the stimulation of cholinergic
post-synaptic muscarinic and nicotinic receptors, and the
reduction of ACh synaptic degradation using AChE inhibi-
tors (e.g., AChEIs or anticholinesterase agents) [12-19].
Acetylcholinesterase inhibitors have beneficial effects on
cognitive, functional, and behavioral symptoms of AD. A
recent review by the Quality Standard Subcommittee of
the American Academy of Neurology investigated impor-
tant issues in the management of dementia. The reviewers
concluded that despite the small average degree of benefit
of treatment with acetylcholinesterase inhibitors they
should be the first-line treatment in patients with mild to
moderate AD [4]. Four cholinesterase inhibitors tacrine,Figure 1 Structures of acetycholinesterase inhibitors in the market.donepezil, rivastigmine, and galantamine are approved by
the US Food and Drug Administration (FDA) and are cur-
rently in the market (Figure 1) [5].
According to the several reports about the efficacy of
phthalimide derivatives in inhibition of AChE, [20-27]
(Figure 2) in the current project, we focused on the de-
sign and synthesis of new anticholinesterase agents with
phthalimide-based structure to reach more active analogs
towards inhibition of AChE. Besides, we hope the new
analogs to render lower side effects. Improving the phar-
macokinetic properties of the designed compounds
could be another aim of this study. In fact, phthalimide
based compounds have similar pharmacophoric portions
like indanone ring of the donepezil and are able to act as
peripheral binding site inhibitor of AChE. We also investi-
gated in silico binding mode of proposed ligands into the
acetylcholinesterase enzyme in comparison with donepezil
as reference drug by docking procedure.
Methods
Preliminary design
In the recent years, there are several reports about the po-
tentiality of phthalimide derivatives as potent anticholines-
terase agents. In fact, the phthalimide-based compounds
can function as inhibitor of the peripheral binding site of
AChE enzyme [20-27]. On the other hands, it is well-
known in medicinal chemistry that piperazine ring can act
as good bioisosteric replacement for piperidine moiety.
According to the Figure 3, we designed a new series
of donepezil-like analogues with replacement of the
indanone and piperidine rings of the donepezil with
A B
Figure 2 Two structures of phthalimide based anticholinesterase.
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zine ring respectively. As illustrated in Figure 3, there are
three distinct and critical portions in the structure of
donepezil. Part A or peripheral binding site portion is
necessary for binding to the AChE enzyme. The phenyl
ring of the indanone moiety of donepezil participates in
π-π stacking interaction with indole ring of Trp 279 in the
active site of AChE. Part B is a linker region as well as an
interacting part with Phe 330 in the active site of the
AChE. According to the structure activity relationship
(SAR) of donepezil-like analogs, the nitrogen atom of the
piperidine ring is necessary for binding to the active site of
the enzyme and removing of the nitrogen can be detri-
mental for anticholinesterase activity of the ligand. In fact,
the charged nitrogen of the piperidine ring makes a
cation-π interaction with Phe 330. Pat C or benzyl moiety
unit plays its role through a π-π stacking interaction with
indole ring of the Trp 84 [16]. Hence, in the designed
compounds (Figure 3), the considering of these threeA B
Figure 3 Design of new donepezil-like analogs based on the phthalimpivotal portions of the donepezil was carried out and sub-
sequently the synthesis of proposed compounds was done.
Chemistry
All chemical substances consisting starter materials, re-
agents and solvents were purchased from the commer-
cial supplier like Merck and Sigma-Aldrich companies.
The purity of the prepared compounds was proved by
thin layer chromatography (TLC) using various solvents
of different polarities. Merck silica gel 60 F254 plates
were used for analytical TLC. Column chromatography
was applied on Merck silica gel (70–230 mesh) for puri-
fication of intermediate and final compounds. 1H-NMR
spectra were recorded using a Bruker 400 MHz spec-
trometer in deutrated solvents, and chemical shifts
are expressed as δ (ppm) with tetramethylsilane (TMS)
as internal standard. The IR spectra were obtained on a
Shimadzu 470 spectrophotometer using potassium
bromide (KBr) disks. Melting points were determinedC
ide structure.
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and are uncorrected. The mass spectra were run on a
Finigan TSQ-70 spectrometer (Finigan, USA) at 70 eV.Synthesis of 2-(2-(piperazin-1-yl)ethyl)isoindoline-1,3-
dione (3)
In a flask 3 g (20 mmol) of Phthalic anhydride, 2.6 ml
(20 mmol) N-amnioethylpiperazine and 2.9 ml (20
mmol) triethylamine (Et3N) were mixed in 40 ml of
toluene solvent. The reaction mixture was refluxed for
24 hours and the termination of reaction and formation
of the desired product was confirmed by thin layer chro-
matography. The discoloration of the reaction medium
and formation of a yellow precipitate was also an indica-
tor of the progress of the reaction. Then, toluene was
evaporated under reduced pressure using rotary evapor-
ator apparatus and the obtained yellow viscose and oily
residue was washed several times by ethyl acetate
(EtOAc) and diethyl ether (Et2O) [28].
1H NMR (CDCl3, 400 MHz) δ (ppm): 2.37 (m, 4H, Piper-
azine), 2.54 (m, 4H, Piperazine), 3.22 (t, 2H, phthalimide-
CH2-CH2-piperazine), 3.44 (t, 2H, phthalimide-CH2-CH2-
piperazine), 4.73 (NH, Piperazine), 7.35-7.85 (m, 4H,
Phthalimide). IR (KBr, cm-1) ῡ: 3380, 3330, 3157, 3111,
2924, 1730, 1681, 1521, 1489, 1458, 1328, 1303, 1186,
1143, 1035, 910, 750, 710. MS (m/z, %): 259 (M+, 10),
224 (30), 174 (30), 160 (60), 149 (85), 99 (100), 70 (70),
57 (65), 41 (40).General procedure for synthesis of compounds 4a-4l:
In a flat-bottom flask equimolar quantities of compound 3
and appropriate derivative of benzyl chloride were added
together in dichloromethane (CH2Cl2) solvent. The reac-
tion mixture was stirred in room temperature overnight.
Then, dichloromethane was evaporated under reduced
pressure and the afforded residue was washed by diethyl
ether and n-hexane. Methanol containing Hydrochloric
acid gas was added to the residue to form the related
hydrochloride salt of the product [29].2-(2-(4-(2-Chlorobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4a)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.36 (m, 8H,
Piperazine), 3.33 (t, 2H, CH2-piperazine), 3.35 (s, 2H, -C
H2-2-Chlorophenyl), 3.61 (t, 2H, -CH2-Phthalimide),
7.25-7.32 (m, 2H, 2-Chlorophenyl), 7.34-7.44 (m, 2H, 2-
Chlorophenyl), 7.46-7.87 (m, 4H, Phthalimide). MS (m/
z, %): 385 (M++2, 2), 383 (M+, 5), 225 (50), 223 (100),
160 (50), 125 (95), 89 (15), 70 (20). IR (KBr, cm-1) ῡ:
3460, 3051, 2943, 2800, 2762, 1766, 1465, 1438, 1396,
1357, 1300, 1192, 1161, 1107, 1041, 921, 759, 717, 698.2-(2-(4-(3-Chlorobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4b)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.34 (m, 4H,
Piperazine), 3.35 (t, 2H, -CH2-piperazine), 3.51 (s, 2H, -
CH2-phenyl), 3.7 (t, 2H, -CH2-phthalimide), 7.27-7.32
(m, H2, H5, 3-Chlorophenyl), 7.41 (d, 1H, J = 8 Hz, H6-
3-Chlorophenyl), 7.45 (d, J = 8 Hz, H4-3-Chlorophenyl),
7.85 (m, 2H, H5,H6-phthalimide), 7.88 (m, 2H, H4,H7-
phthalimide). IR (KBr, cm-1) ῡ: 3160, 3113, 2924, 1710,




1H NMR (CDCl3, 400 MHz) δ (ppm): 2.2 (t, 2H, -N-
CH2-CH2-NH-, piperazine), 2.5 (t, 2H, -N-CH2-CH2-NH-,
Piperazine), 2.63 (t, 2H, phthalimide-CH2-CH2-piperazine),
3.42 (s, 2H, -CH2-phenyl), 3.8 (t, 2H, phthalimide-
CH2-CH2-piperazine), 7.23 (d, 2H, J = 8 Hz, H2,6-4-
chlorophenyl), 7.30 (d, 2H, J = 8 Hz, H3,5-4-chlorophenyl
phenyl), 7.76 (m, 4H, Phthalimide). IR (KBr, cm-1) ῡ: 3400,
3380, 3135, 3111, 2927, 2812, 1703, 1681, 1533, 1521,
1489, 1456, 1328, 1305, 1186, 1143, 1035, 721, 707. MS
(m/z, %): 384 (M+ +1, 20), 383 (M+, 18), 280 (20), 223
(100), 167 (30), 149 (90), 125 (90).
2-(2-(4-(2-Fluorobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4d)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.4 (m, 4H,
piperazine), 3.1 (m, 4H, aliphatic), 3.8 (s, 2H, -CH2-
phenyl), 7.35 (m, 4H, 2-Fluorophenyl), 7.88 (m, 4H,
Phthalimide). IR (KBr, cm-1) ῡ: 3429, 2993, 2924, 2854,
1774, 1716, 1396, 1068, 1010, 721. MS (m/z, %): 368
(M++1, 25), 313 (40), 285 (35), 257 (40), 236 (100), 152
(40), 111 (60), 97 (95), 83 (90), 69 (90), 57 (85), 43 (50).
2-(2-(4-(3-Fluorobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4e)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 3.37-3.87 (m,
aliphatic), 3.99 (s, 2H, -CH2-phenyl), 7.29 (d, 1H, J = 8 Hz,
H2-3-Fluorophenyl), 7.49 (m, 1H, H6-3-Fluorophenyl),
7.66 (d, 1H, J = 8 Hz, H5-3-Fluorophenyl), 7.68 (d, 1H,
J = 8 Hz, H3-3-Fluorophenyl), 7.86-7.88 (m, 4H, phthal-
imide). IR (KBr, cm-1) ῡ: 3371, 2993, 2958, 2924, 2854,
1774, 1712, 1546, 1462, 1404, 1056, 972, 721.
2-(2-(4-(4-Fluorobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4f)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 3.99 (m, 12H,
aliphatic), 3.96 (s, -CH2-phenyl), 3.99 (t, 2H, -CH2-
phthalimide), 7.3 (t, 2H, J = 8 Hz, 4-Fluorophenyl), 7.58-
7.73 (m, 4-Fluorophenyl), 7.83-7.88 (m, 4H, Phthalimide).
IR (KBr, cm-1) ῡ: 3367, 2997, 2854, 1774, 1716, 1604,
1512, 1462, 1400, 1056, 975, 721.
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1,3-dione (4g)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 3.2-3.66 (m,
aliphatic), 3.79 (s, 3H, -OCH3), 3.97 (s, 2H, -CH2-
phenyl), 7.1-7.36 (m, 4H, 4-Methoxyphenyl), 7.58-7.66
(m, 4H, Phthalimide). IR (KBr, cm-1) ῡ: 3371, 2993,
1774, 1716, 1612, 1462, 1435, 1400, 1381, 1269, 1056,
972, 906, 798, 721. MS (m/z, %): 379 (M+, 15), 219
(100), 160 (30), 121 (80), 91 (20).
2-(2-(4-(4-Methoxybenzyl)piperazin-1-yl)ethyl)isoindoline-
1,3-dione (4h)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 3.1-3.78 (m,
aliphatic), 3.78 (s, 3H, -OCH3), 4.4 (s, 2H, -CH2-phenyl),
7.1 (dd, 4H, J = 8 Hz, 4-Methoxyphenyl), 7.43-7.58 (m,
4H, Phthalimide). IR (KBr, cm-1) ῡ: 3429, 2978, 2935,
1778, 1716, 1612, 1516, 1462, 1435, 1400, 1235, 1184,
1072, 1029, 802, 725.
2-(2-(4-(2-Nitrobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4i)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.25-2.35 (m,
8H, Piperazine), 3.35 (t, 2H, -CH2-piperazine), 3.66 (s,
2H, CH2-phenyl), 3.68 (t, 2H, -CH2-phthalimide), 7.4-
7.66 (m, 4H, 2-Nitrophenyl), 7.83-7.89 (m, 4H, Phthal-
imide). IR (KBr, cm-1) ῡ: 3155, 3111, 2956, 2922, 1681,
1521, 1489, 1458, 1327, 1303, 1188, 1141, 1035, 740,
717, 705. MS (m/z, %): 394 (M+, 3), 377 (15), 259 (30),
235 (40), 234 (100), 200 (50), 160 (70), 130 (30), 99 (55),
78 (30) 56 (15).
2-(2-(4-(3-Nitrobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4j)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.51 (m, 4H,
Piperazine), 3.53 (t, 2H, -CH2-piperazine), 3.79 (s, -CH2-
phenyl), 3.85 (t, 2H, -CH2-phthalimide), 7.6-7.66 (m, 2H,
H4,6-3-Nitrophenyl), 7.65 (s, 1H, H2-3-Nitrophenyl), 7.75
(t, J = 8 Hz, 1H, H5-3-Nitrophenyl), 7.85 (m, 2H, H5,6-
phthalimide), 7.88 (m, 2H, H4,7-phthalimide). IR (KBr,
cm-1) ῡ: 3425, 2924, 2854, 1774, 1716, 1531, 1435, 1400,
1350, 1060, 806, 721.
2-(2-(4-(4-Nitrobenzyl)piperazin-1-yl)ethyl)isoindoline-1,3-
dione (4k)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.3 (m, 8H, Piper-
azine), 3.33 (t, 2H, phthalimide-CH2-CH2-piperazine), 3.56
(s, 2H, -CH2-phenyl), 3.69 (t, 2H, phthalimide-CH2-CH2-
piperazine), 7.57 (d, 2H, J = 8 Hz, H2,6-4-Nitrophenyl),
7.83-7.88 (m, 4H, Phthalimide), 8.19 (d, 2H, J = 8 Hz, H3,5-
4-Nitrophenyl). IR (KBr, cm-1) ῡ: 3157, 3111, 2924, 1775,
1681, 1519, 1489, 1458, 1330, 1303, 1186, 1143, 1037, 750,
710. MS (m/z, %): 395 (M++1, 10), 394 (M+, 35), 235 (85),
234 (100), 191 (60), 174 (30), 160 (85), 90 (25), 70 (40).2-(2-(4-Benzylpiperazin-1-yl)ethyl)isoindoline-1,3-dione (4l)
1H NMR (DMSO-d6, 400 MHz) δ (ppm): 2.51 (m, 4H,
Piperazine), 3.55 (m, 8H, aliphatic), 3.99 (s, 2H, -CH2-
phenyl), 7.45-7.68 (m, 4H, phenyl), 7.85 (m, 4H,
Phthalimide). IR (KBr, cm-1) ῡ: 3414, 2997, 2924, 1774,
1712, 1635, 1431, 1396, 1064, 721. MS (m/z, %): 349
(10), 234 (20), 189 (100), 160 (35), 91 (90).
Anticholinesterase activity assay (Ellman test)
Lyophilized powder of acetylcholinesterase from elec-
tric eel source (AChE, E.C. 3.1.1.7, Type V-S, 1000
unit) was purchased from Sigma-Aldrich (Steinheim,
Germany). 5,5’-Dithiobis-(2-nitrobenzoic acid), pota-
ssium dihydrogen phosphate, dipotassium hydrogen
phosphate, potassium hydroxide, sodium hydrogen car-
bonate, and acetylthiocholine iodide were purchased from
Fluka (Buchs, Switzerland). Compounds 4a-4l were
dissolved in a mixture of 20 ml distilled water and 5 ml
methanol and then diluted in 0.1 M KH2PO4/K2HPO4
buffer (pH 8.0) to afford a final concentration range. The
Ellman test was carried out for assessment of the anticho-
linesterase activity of intended compounds in vitro. Prior
to use, all solutions were adjusted to 25°C. To achieve 20-
80% inhibition of AChE activity five different concentra-
tions of each compound were tested. The assay solution
consisted of a 0.1 M potassium phosphate buffer pH 8.0,
with the addition of 0.01 M 5,50-dithio-bis(2-nitrobenzoic
acid), 2.5 unit/mL of enzyme solution (AChE, E.C. 3.1.1.7,
Type V-S, lyophilized powder, from electric eel) (Sigma
Chemical). Compounds 4a-4l were added to the assay
solution and preincubated at 25°C with the enzyme for
15 min followed by adding 0.075 M substrate (acetyl-
thiocholine iodide). After rapid and immediate mixing the
change of absorption was measured at 412 nm. In order to
justify non enzymatic reaction assays were carried out
with a blank containing all components except AChE.
The blank reading contained 3 ml buffer, 200 μl water,
100 μl DTNB and 20 μl substrate. The reaction rates
were calculated, and the percent inhibition of test com-
pounds was determined. Each concentration was ana-
lyzed in triplicate, and IC50 values were determined
graphically from inhibition curves (log inhibitor concen-
tration vs percent of inhibition). Spectrophotometric
measurements were performed on a Cecil BioAquarius
CE 7250 Double Beam Spectrophotometer [30].
Docking
ArgusLab 4.0 software was applied to perform molecu-
lar docking studies [31,32]. All intended ligands were
constructed in arguslab workspace and all ligands 4a-4l
were energy minimized by AM1 as semiemperical
method. The pdb file of acetylcholinesterase enzyme in
complex with donepezil (pdb code: 1EVE) was downloaded
from brookhaven protein databank [33]. The geometry
Figure 4 Docked molecule of compound 4a in the active site of AChE (PDB code: 1EVE). The principal amino acids (Trp 279, Phe 330, Trp
84) are evident in the nearby of the docked molecule.
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was performed using universal force field (UFF) as a mo-
lecular mechanic method. The docking process was done
for all ligands in the workspace of ArgusLab 4 software
after defining the related groups for each ligand and also
for related protein. The binding location of donepezil was
defined as binding site for finding the best pose and con-
formation for all ligands. Binding mode and related interac-
tions of all ligands were explored in Molegro molecular
viewer software (Figure 4, Figure 5) [34].
Results and discussion
Chemistry
As summarized in the Scheme 1, all intermediate and
final compounds 3 and 4a-4l were synthesized with anFigure 5 Superimposed structure of compound 4a with donepezil in
donepezil are observed for compound 4a.acceptable to high yield (ranging 61–96%) as listed in
Table 1. Compound 3 was obtained through a Gabriel
synthetic reaction. Reaction of phthalic anhydride with
N-aminoethylpiperazine afforded the compound 3 with
61% yield. The reaction was carried out under reflux
conditions in toluene solvent. Washing of yellowish oily
product was done by ethyl acetate and n-hexane. A yel-
low powder was obtained after trituration. Obtained
product was used for synthesis of 4a-4l derivatives.
Room temperature stirring of equimolar quantities of
compound 3 with appropriate benzyl chloride derivatives
afforded 4a-4l derivatives. Dichloromethane was used as
solvent and overnight stirring is necessary for achieving
an acceptable yield. After evaporation, an oily residue
was obtained. Methanolic hydrochloric acid was appliedthe active site of AChE. A similar binding mode and interaction like
Scheme 1 Synthetic pathway of compounds 4a-4l.
Mohammadi-Farani et al. DARU Journal of Pharmaceutical Sciences 2013, 21:47 Page 7 of 9
http://www.darujps.com/content/21/1/47to form the corresponding hydrochloride salt of each de-
rivative. For each compound 2 ml of methanolic solvent
was added to the obtained residue and stirred at room
temperature for 5–10 minutes. The formed precipitate
was filtered, dried and collected.
Different types of substituent consisted of three elec-
tron withdrawing substituents (Cl, F, NO2) and also an
electron donating substituent (−OCH3) were synthesized
to investigate the electronic effects of various moieties.
Furthermore, compound 4l was also synthesized without
any group on the phenyl ring to explore the effect of the
presence of the substitution on this ring.Table 1 Properties of synthesized compounds
Compounds R Closed formula MW
3 - C14H17N3O2
4a 2-Cl C21H22 Cl N3O2
4b 3-Cl C21H22 Cl N3O2









4l H C21H23N3OMelting points of intermediate and final compounds
were obtained using capillary tubes by electrothermal
melting point analyzer. A range in melting point was
recorded for compounds 3, 4a, 4b, 4f and 4i. In other
cases a sharp point was detected and presented in
Table 1. 1H NMR, IR and MS spectroscopic methods
were applied for characterization and identification of all
compounds. Deutrated dimethyl sulfoxide (DMSO-d6)
was used for 1H NMR acquisition and TMS (tetramethyl
silane) was applied as internal standard. Infrared spec-
troscopy was performed for all compounds using KBr
disk and outstanding peaks was reported. Molecular ion(g/mol) mp (°C) Yield (%) Appearance
259 105-109 61 Yellow
383 105-107 81 Creamy
383 100-103 74 Creamy
383 122 78 Creamy
367 226 96 Yellow
367 225 77 Creamy
367 293-296 77 Yellow
379 259 82 Yellow
379 265 65 Yellow
394 118-120 78 Orange
394 286 92 Orange
394 162 80 Creamy
349 231 92 Orange
Table 2 Results (IC50, μM) of in vitro acetylcholinesterase assay of compounds 4a-4l
Compound 4a 4b 4c 4d 4e 4f 4g 4h 4i 4j 4k 4l Donepezil
R 2-Cl 3-Cl 4-Cl 2-F 3-F 4-F 3-OCH3 4-OCH3 2-NO2 3-NO2 4-NO2 H -
IC50(μM) 0.91 ± 0.045 85 ± 12 26 ± 5 23 ± 7 74 ± 11 42 ± 8 5.5 ± 0.7 72 ± 9 36 ± 5 59 ± 6 40 ± 4 9 ± 2 0.14 ± 0.03
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spectroscopy. Furthermore, M++2 was also reported for
chlorinated compounds.
Anticholinesterase activity
According to Table 2, all compounds 4a-4l were tested
against acetylcholinesterase and related IC50 ± SEM were
calculated. Compound 4a with ortho chlorine substituent
on phenyl ring was the most potent one in this series
(IC50 = 0.91 ± 0.045 μM). Para position (compound 4c,
IC50 = 26 ± 5 μM) was also favorable for anticholinester-
ase activity but on the other hands meta substitution of
chlorine (compound 4b, IC50 = 85 ± 12 μM) led to the
lowest inhibitory effect compared to other position for
this moiety. Among compounds 4d-4f with fluorine moi-
ety, compound 4d at position 2(ortho) showed the highest
inhibitory property toward the acetylcholinesrase. Position
3(meta) was the worst position for fluorine and para sub-
stitution afforded an averaged potency in comparison with
other positions. Compound 4g with meta substitution of
methoxy substituent as electron donating group rendered
a high potency derivative with IC50 = 5.5 ± 0.7 μM. A simi-
lar trend like chlorine and fluorine moieties was also
observed for nitro group. Substitution of nitro group as
electron withdrawing moiety at position 2(ortho) of the
phenyl ring in compound 4i afforded the best effect. On
the other hands, position 3(meta) was the worst position
for nitro substituent (compound 4j). Insertion of nitro
group at position 4(para) in compound 4k led to a moder-
ate affinity for inhibition of acetylcholinesterase compared
to positions 2 and 3. Compound 4l without any substitu-
ent on the phenyl ring was also one of the most potent in-
hibitor of acetylcholinesterase in this series. Totally,
electron withdrawing moieties such as Cl, F and NO2 at
position 2(ortho) of the phenyl ring can enhance the
potency of synthesized phthalimide derivatives. Electron
donating group like methoxy at position 3 can also in-
crease the enzyme inhibitory effects in these series.
Totally, electron withdrawing substituents are capable
to enhance the anticholinestease activity of the
phthalimide derivatives that synthesized in this re-
search. Comparison of the different compounds with
electron withdrawing moieties showed that ortho pos-
ition is the best position for this type of substituents.
Whereas, the para position was the worst position for
all of the electron withdrawing moieties. Introducing of
an electron donating group such as methoxy at meta
position of the phenyl ring also led to the increasing ofthe potency. But, this change was not so effective like
ortho substitution of chlorine atom. Absence of any
moiety on the phenyl ring as observed about compound
4l could be an AChE inhibitor with an averaged po-
tency. In fact, this compound exerted potency less than
compound 4a with ortho chlorine as well as compound
4g with meta methoxy substituent.
Molecular modeling
All ligands 4a-4l were docked into the active site of
acetylcholinesterase (PDB ID: 1EVE). For performing
an accurate docking procedure, the binding site of
donepezil was intended as probable binding site for all
ligands especially for ligand 4a. Compound 4a as the
best inhibitor of AChE in vitro was studied in silico to
reveal the probable binding mode of synthesized com-
pounds perfectly (Figure 3). Superimposed state for this
ligand with donepezil was also explored. According to
the Figure 4, a similar binding mode and conformation
as observed for donepezil, was also seen for this ligand.
In fact, the structure of synthesized compounds occupies
a similar region like donepezil in the active site of AChE.
As seen in Figure 4, phthalimide, piperazine and benzyl
rings of compound 4a adopt a same location like
indanone, piperidine and benzyl rings of the donepezil
respectively.
Conclusions
A new series of donepezil-like analogs were synthesized
based on the phthalimide structure and anticholinesterase
activity was assessed using Ellman test. All compounds
exhibited a μM range in IC50 value (5.5-85 μM) for inhib-
ition of AChE except for compound 4a that exhibited a
nM range in IC50 value (0.91 μM). In silico study of com-
pound 4a by docking method was also confirmed a similar
binding mode like donepezil for this ligand.
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